标题
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
作者
关键词
Indoleamine 2,3-dioxygenase, IDO inhibitors, Immune surveillance, Immunomodulatory, Malignancy
出版物
Journal for ImmunoTherapy of Cancer
Volume 3, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-10-22
DOI
10.1186/s40425-015-0094-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
- (2014) George C. Prendergast et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
- (2014) Mario R. Mautino et al. CANCER RESEARCH
- Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!
- (2014) M. G. Castro et al. CLINICAL CANCER RESEARCH
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- Spontaneous Renal Allograft Acceptance Associated with "Regulatory" Dendritic Cells and IDO
- (2014) C. H. Cook et al. JOURNAL OF IMMUNOLOGY
- The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation
- (2014) W. Chen et al. JOURNAL OF IMMUNOLOGY
- Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
- (2014) M. V. Dhodapkar et al. Science Translational Medicine
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
- (2014) Minghui Li et al. Journal for ImmunoTherapy of Cancer
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
- (2012) M. Platten et al. CANCER RESEARCH
- Regulation of Expression and Function of IDO in Human Dendritic Cells
- (2012) A. Heitger CURRENT MEDICINAL CHEMISTRY
- Indoleamine 2,3-dioxygenase, Tregs and Cancer
- (2012) D. H. Munn CURRENT MEDICINAL CHEMISTRY
- Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
- (2012) Theodore S. Johnson et al. IMMUNOLOGICAL INVESTIGATIONS
- Indoleamine 2,3 dioxygenase and metabolic control of immune responses
- (2012) David H. Munn et al. TRENDS IN IMMUNOLOGY
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
- (2011) Eduard Dolušić et al. JOURNAL OF MEDICINAL CHEMISTRY
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells
- (2011) Huai-Chia Chuang et al. NATURE IMMUNOLOGY
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive Mice
- (2010) Madhav D. Sharma et al. IMMUNITY
- Dendritic Cells, Indoleamine 2,3 Dioxygenase and Acquired Immune Privilege
- (2010) Lei Huang et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
- (2010) H. K. Koblish et al. MOLECULAR CANCER THERAPEUTICS
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
- (2010) N. T. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
- (2009) D. J. Chung et al. BLOOD
- Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes
- (2009) M. D. Sharma et al. BLOOD
- Halofuginone Inhibits TH17 Cell Differentiation by Activating the Amino Acid Starvation Response
- (2009) M. S. Sundrud et al. SCIENCE
- Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
- (2009) S. Rutella et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
- (2008) A. Curti et al. BLOOD
- IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
- (2008) Stefan Löb et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
- (2008) K. Ino et al. CLINICAL CANCER RESEARCH
- Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges
- (2008) Jianchao Quan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase–dependent mechanism
- (2008) Olivier Manches et al. JOURNAL OF CLINICAL INVESTIGATION
- Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors
- (2008) Sanjeev Kumar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ
- (2008) Selim Corm et al. LEUKEMIA RESEARCH
- Neuropsychiatric disorders related to interferon and interleukins treatment
- (2008) Aye Mu Myint et al. METABOLIC BRAIN DISEASE
- Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
- (2007) L. K. Jasperson et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More